BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17998303)

  • 1. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
    Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
    J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
    Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
    Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
    Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
    Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G
    Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
    Castro JE; Prada CE; Aguillon RA; Kitada S; Fukuda T; Motta M; Wu C; Dicker F; Sun G; Wang JY; Carson DA; Reed JC; Kipps TJ
    Leukemia; 2006 Apr; 20(4):680-8. PubMed ID: 16498393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Barbarotto E; Corallini F; Rimondi E; Fadda R; Mischiati C; Grill V; Vaccarezza M; Celeghini C
    J Cell Biochem; 2008 May; 104(2):595-605. PubMed ID: 18092340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
    Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
    Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
    Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
    Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
    Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
    Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
    Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway.
    Browning RL; Mo X; Muthusamy N; Byrd JC
    Oncotarget; 2015 Jun; 6(18):15931-9. PubMed ID: 26158860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
    Hagn M; Blackwell SE; Beyer T; Ebel V; Fabricius D; Lindner S; Stilgenbauer S; Simmet T; Tam C; Neeson P; Trapani JA; Schrezenmeier H; Weiner GJ; Jahrsdörfer B
    Int Immunol; 2014 Jul; 26(7):383-95. PubMed ID: 24497611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
    J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.